IMMP News and Press, Immutep Limited From 06/12/22

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go. For further details see: Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) presents TACTI-002 data at ASCO 2022 - Slideshow

Australian biotech Immutep Limited (NASDAQ:IMMP) announced new data from its Phase II TACTI-002 trial on Friday, highlighting the efficacy of its lead candidate eftilagimod alpha in combination with Merck’s (MRK) anti-PD1 therapy Keytruda in 1st line non-small cell lung cancer (NSCLC)....

TACTI-002 has met its primary objective for 1 st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114) Combination of efti plus pembrolizumab shows favourable anti-tumour activity: Improved Ove...

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) Investor Presentation - Slideshow

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global...

Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1 st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022 Improved Overall Response Rate (ORR) of 37.3% (intent to treat, 28/75 patients) as assessed...

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has b...

SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limi t ed (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced...

Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...